SCTX (Scribe Therapeutics) Total Receivables: $1.52 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics Total Receivables?

Scribe Therapeutics SCTX -13.40% 8 Total Receivables is $1.52 Mil as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

Scribe Therapeutics's Total Receivables for the quarter that ended in Mar. 2026 was $1.52 Mil.

Scribe Therapeutics Total Receivables Related Terms

Scribe Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics Total Receivables Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
Total Receivables
3.52 7.35

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Total Receivables 3.52 0.00 7.35 1.52
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $1.52 Mil mean?
Scribe Therapeutics (SCTX) has a Total Receivables of $1.52 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' Total Receivables too high?
Scribe Therapeutics' current Total Receivables is $1.52 Mil. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' Total Receivables compare to ?
Scribe Therapeutics' Total Receivables of $1.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current Total Receivables is $1.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current Total Receivables of $1.52 Mil. The current Total Receivables is $1.52 Mil. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current Total Receivables is $1.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price